Liposomal Fenretinide Formulations Overcoming Oral Absorption Limits
Solution Overview
Problem
Current formulations of fenretinide (HPR) for cancer treatment face limitations due to poor solubility and absorption, leading to suboptimal plasma levels, which restrict its effectiveness as a chemotherapeutic agent, especially in achieving cytotoxic concentrations required to inhibit tumor cells.
Innovation Solution
Development of novel lipid nanoparticle and emulsion formulations that enhance the solubility and bioavailability of fenretinide, allowing for higher and sustained plasma and tissue levels, enabling effective intravenous administration and overcoming the limitations of oral dosing.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Quantity of substance
If fenretinide is administered orally in corn oil suspension, then the drug can be delivered to patients, but plasma concentrations cannot exceed a ceiling level of approximately 5 μg/mL regardless of dose escalation
Solution Approach 1:
The patent changes the physical and chemical parameters of the formulation by transitioning from oral corn oil suspension to parenteral (intravenous) administration of liposomal or emulsion formulations. This parameter change bypasses the saturable absorption mechanism of oral delivery, enabling plasma concentrations to exceed the 5 μg/mL ceiling and reach cytotoxic levels necessary for chemotherapy.
Solution Approach 2:
The patent introduces lipid-based carriers (liposomes or emulsions) as intermediaries to deliver fenretinide. These carriers solubilize the poorly water-soluble drug and facilitate its intravenous administration, acting as a mediator between the drug and the bloodstream to achieve sustained high plasma concentrations that overcome the oral absorption limitation.
2Quantity of substance
If the dose of fenretinide is escalated above chemoprevention levels to achieve chemotherapeutic effect, then cytotoxic levels may be reached, but absorption saturation prevents further increase in plasma levels
Solution Approach 1:
Lipid-based carriers serve as intermediaries that bypass the saturable absorption pathway. By encapsulating fenretinide in liposomes or emulsions for intravenous delivery, the formulation eliminates the absorption bottleneck entirely, allowing reliable achievement of high plasma concentrations without being constrained by absorption saturation.
Solution Approach 2:
The route of administration is changed from oral to parenteral, fundamentally altering the pharmacokinetic parameters. This parameter change eliminates first-pass metabolism and saturable absorption, enabling reliable and predictable achievement of high plasma concentrations necessary for chemotherapeutic effect.
3Quantity of substance
If fenretinide is formulated in water-soluble lipid vesicles or emulsions, then solubility and bioavailability are enhanced, but the formulation complexity increases
Solution Approach 1:
The patent changes the physical state and solubility parameters of fenretinide by incorporating it into lipid-based carriers. This parameter change transforms the drug from a poorly water-soluble compound to a formulation with enhanced solubility and bioavailability, while the complexity is managed through established liposomal and emulsion technologies.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The formulations achieve and maintain therapeutic plasma concentrations of fenretinide, exceeding the levels necessary for cytotoxicity against tumor cells, thereby enhancing the efficacy of fenretinide as a cancer treatment, particularly in pancreatic cancer and other solid tumors.
Implementation Method 1
HPR and other neutral retinoids exhibit very low water solubility and high octanol:water partition coefficients... solubilizing HPR in water soluble (amphipathic) lipid vesicles or emulsions to take advantage of its natural affinity for lipid membranes
Implementation Method 2
HPR acting independently of retinoid receptors RAR or RXR, induced apoptosis in human tumor cell lines... HPR had a favorable safety profile after parenteral administration
Data Source
AI summary
Formulations of neutral retinoids, in particular fenretinide (HPR) in the form of lipid nanoparticles, solid dipersions and emulsions are disclosed. These compositions are used to treat diseases that are amenable to treatment by HPR, such as neoplastic diseases by achieving higher and more prolonged concentrations of HPR in the subject. The key steps for preparing lipid nanovesicles of HPR include mixing and sonication, sterile filtration, without or without lyophilization for long-term stable storage, and employ processes and materials that are scalable from the laboratory to the manufacturing level. The formulation are suitable for injection into human or animal patients without causing allergic or hypersensitivity responses by avoiding chemical surfactants and animal sources of phospholipids in their manufacture.